Nymox Pharmaceutical (NYMXF) 6-K 13 May 22 2022 Q1 Current report (foreign) Financial data

Cover

Cover	3 Months Ended
	Mar. 31, 2022
Cover [Abstract]
Entity Registrant Name	Nymox Pharmaceutical Corporation
Entity Central Index Key	0001018735
Document Type	6-K
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Entity File Number	001-12033
Entity Address Postal Zip Code	20549

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues
Sales Of Goods	$ 0	$ 0
Total Revenues	0	0
Cost Of Goods Sold And Operating Expenses
Cost Of Goods Sold	0	0
Research And Development	4,334	1,425
General And Administrative	740	1,004
Total Operating Expenses	5,074	2,429
Loss From Operations	(5,074)	(2,429)
Other Income (expense)
Finance Expense	(3)	1
Operating Lease Interest Expense	(6)	(5)
Loss Before Income Tax	(5,086)	(2,439)
Income Tax Provision (recovery)	0	0
Net Loss	(5,086)	(2,439)
Attributable To:
Net Loss Attributable To Nymox Share Holders	$ (5,086)	$ (2,439)
Basic And Diluted Loss Per Share	$ (0.06)	$ (0.03)
Weighted Average Number Of Common Shares Outstanding	86,027	77,969

Consolidated Statements of Fina

Consolidated Statements of Financial Position (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current Assets
Cash At Bank	$ 672	$ 830
Other Receivables	10	13
Inventory	34	34
Security Deposit	28	28
Prepaid Expenses And Other Current Assets	146	132
Total Current Assets	890	1,037
Non-current Assets
Property And Equipment	19	22
Operating Lease Right-of-use Asset, Net	329	384
Total Assets	1,238	1,443
Current Liabilities
Accounts Payable And Accrued Liabilities	2,289	1,558
Operating Lease Liability Due Within One Year	231	228
Total Current Liabilities	2,520	1,786
Long Term Operating Lease Liability	108	163
Total Liabilities	2,628	1,949
Equity
Share Capital - Unlimited Authorized Shares At No Par Value 90,280 And 85,546 Shares Outstanding At March 31, 2022 And December 31, 2021, Respectively	170,915	165,061
Share Capital Subscription Receivable	(2,489)	(589)
Additional Paid-in Capital	27,832	27,584
Accumulated Deficit	(197,648)	(192,562)
Total Stockholders' equity	(1,390)	(506)
Total Liabilities And Stockholders' Equity	$ 1,238	$ 1,443

Consolidated Statements of Fi_2

Consolidated Statements of Financial Position (Parenthetical) - shares shares in Thousands	Mar. 31, 2022	Dec. 31, 2021
Consolidated Statements of Financial Position (Unaudited)
Share capital, shares outstanding	90,280	85,546

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (5,086)	$ (2,439)
Stock-based compensation	94	282
Depreciation	(3)	(3)
AmortizationAndOthers	(61)	(61)
Accounts receivable and other receivables	3	5
Prepaid expense	(14)	(96)
Inventory	0	0
Accounts payable and accrued liabilities	732	(677)
Net cash used in operating activities	(4,207)	(2,669)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	0	(2)
Net cash flows used in investing activities		(2)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the issuance of share capital &warrants	4,108
Repayment of operating lease and financing obligation	(59)	60
Net cash flows used in financing activities	(4,049)	(60)
Net decrease in cash and cash equivalents	158	2,731
CASH AT BANK
CashBeginning of the period	830	3,611
Cah End of the period	672	880
NON-CASH INVESTING AND FINANCING ACTIVITIES
Operating lease right-of-use asset and related liability	$ 0	$ 0

Consolidated Statements of Chan

Consolidated Statements of Changes in (Deficit) Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Share Capital Subscription	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Dec. 31, 2020		77,961
Balance, amount at Dec. 31, 2020	$ 2,145	$ 151,722	$ (589)	$ 31,037	$ (180,025)
Statement [Line Items]
Stock-based compensation, shares		750
Stock-based compensation, amount	282	$ 1,020	0	(738)
Net loss	(2,439)				(2,439)
Balance, amount at Mar. 31, 2021	(12)	$ 152,742	(589)	30,299	(182,464)
Balance, shares at Mar. 31, 2021		78,711
Balance, shares at Dec. 31, 2021		85,546
Balance, amount at Dec. 31, 2021	(506)	$ 165,061	(589)	27,584	(192,562)
Statement [Line Items]
Net loss	(5,086)	$ 0		0	(5,086)
Share issuance for cash and share subscription, shares		3,984
Share issuance for cash and share subscription, amount	2,366	$ 4,834	(1,900)	(568)	0
Warrant issued	1,741
Stock-based compensation and service fee, Shares		750
Stock-based compensation and service fee, amount	95	$ 1,020	0	(925)	0
Balance, amount at Mar. 31, 2022	$ (1,390)	$ 170,915	$ (2,489)	$ 27,832	$ (197,648)
Balance, shares at Mar. 31, 2022		90,280

Basis of preparation

Basis of preparation	3 Months Ended
	Mar. 31, 2022
Basis of preparation	1. Basis of preparation: (a) Statement of compliance: The consolidated condensed unaudited interim consolidated financial statements of the Corporation have been prepared in accordance with International Financial Reporting Standards (“IFRS”) and its interpretations as issued by the International Accounting Standards Board (“IASB”) and in accordance with IAS 34, Interim Financial Reporting The consolidated condensed interim consolidated financial statements were authorized for issuance by the Board of Directors on May 13, 2022. (b) Basis of measurement: The condensed unaudited interim consolidated financial statements have been prepared on a going concern and on the historical cost basis. The functional currency of the Corporation is the US dollar. (c) Use of estimates and judgments: The preparation of the consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. Information about critical judgments in applying accounting policies and assumption and estimation uncertainties that have the most significant effect on the amounts recognized in the consolidated financial statements is noted below: Significant estimates include, but are not limited to, the estimation of useful lives of equipment for purposes of depreciation, useful life of lease for purpose of amortization and the valuation of common shares and stock option issued for services.

Liquidity, Going Concern and Ma

Liquidity, Going Concern and Managements Response	3 Months Ended
	Mar. 31, 2022
Liquidity, Going Concern and Management's Response	2. Liquidity, Going Concern and Management’s Response Management believes that current cash balances as of March 31, 2022 and planned fund raising is sufficient to finance the Company’s operations for at least the next 12 months. However the Company intends to seek additional equity or other financing, should the Company’s liquidity needs change. Considering recent developments and the need for additional financing, there exists a material uncertainty that casts substantial doubt about the Corporation’s ability to continue as a going concern. These financial statements do not reflect adjustments that would be necessary. If the going concern assumption is not appropriate, then adjustments may be necessary to the carrying value and classification of assets and liabilities and reported results of operations and such an adjustment could be material.

Share capital

Share capital	3 Months Ended
	Mar. 31, 2022
Share capital	3. Share capital: The holders of common shares are entitled to receive dividends as declared, which is at the discretion of the Corporation, and are entitled to one vote per share at the annual general meeting of the Corporation. The Corporation has never paid any dividends. (a) Private placements: On March 18,2022, the company entered into a definitive agreement with institutional investors in a private placement of 3,878,789 shares of common stock and warrants to purchase 3,878,789 shares of common stock at a combined purchase price of $1.65 per share for gross proceeds of approximately $6,400,000 before deducting fees and other estimated offering expenses. The investor warrants have an exercise price of $2.00 per share, is immediately exercisable and will expire five years from the Effective Date. A.G.P./Alliance Global Partners is acting as sole placement agent for the private placement. On March 22, the company closed its financing. (b) Stock options: The Corporation has established a stock option plan (the “Plan”) for its key employees, its officers and directors, and certain consultants. The Plan is administered by the Board of Directors of the Corporation. The Board may from time to time designate individuals to whom options to purchase common shares of the Corporation may be granted, the number of shares to be optioned to each, and the option price per share. The option price per share cannot involve a discount to the market price at the time the option is granted. The maximum number of shares which may be optioned under the stock option plan is 15,000,000. The maximum number of shares which may be optioned to any one individual is 15% of the total issued and outstanding common shares. Options under the Plan expire ten years after the grant date and vest either immediately or over periods up to six years, and are equity-settled. As of March 31, 2022, 8,572,000 options could still be granted by the Corporation. The following table provides the activity of stock option awards during the three-month period ended March 31, 2022 and for options outstanding and exercisable at the end of the three-month period ended March 31, 2022, the weighted average exercise price and the weighted average years to expiration. Options outstanding Weighted Weighted average average remaining exercise contractual Number Price life (in years) Outstanding, December 31, 2021 6,428,000 $ 1.81 3.86 Expired - - - Cancelled - - - Granted - - - Outstanding, March 31, 2022 6,428,000 $ 1.81 3.61 Options exercisable 6,361,333 $ 1.80 3.57 (c) Stock-based compensation: Stock -based compensation includes stock and stock option granted to employees and contractors for their service. Three months ended March 31, Employee expense 2022 2021 Stock and stock option compensation granted in 2015 62,267 229,188 2020 32,369 52,858 Total stock-based compensation expense recognized $ 94,636 $ 282,046 The stock and stock option -based compensation expense is disaggregated in the statements of operations and comprehensive loss as follows: Three months ended March 31, 2022 2021 Stock-based compensation pertaining to general and administrative expenses $ 31,133 $ 114,594 Stock-based compensation pertaining to research and development expenses 63,503 167,452 Total $ 94,636 $ 282,046 (d) Warrants: In the first quarter of 2019, the Corporation issued 2,500,000 warrants in connection with one private placement. Each warrant entitles the holder to acquire one common share of the Corporation at an exercise price of $8.00 with a seven year term. The warrants were valued at $200,000 and recorded as part of additional paid in capital. In the second quarter of 2021, the Corporation issued 2,018,348 warrants in connection with one private placement. Each warrant entitles the holder to acquire one common share of the Corporation at an exercise price of $2.50 with a five year term. The warrant was recorded as part of additional paid in capital at a total of $330,277. In the first quarter of 2022, the Corporation issued 3,878,789 investor warrants in connection with one private placement. Each warrant entitles the holder to acquire one common share of the Corporation at an exercise price of $2.00 with a five year term. In addition, the Company issued Placement Agent (or its assigns) warrants to purchase up to 193,939 shares of common stock at an exercise price of $2.06 per share, The Placement Agent Warrants are immediately exercisable and will expire on the five-year anniversary of the Effective Date, The warrants were recorded as part of additional paid in capital at a total of $1,877,608.

Earnings per share

Earnings per share	3 Months Ended
	Mar. 31, 2022
Earnings per share
Earnings per share:	4. Earnings per share: Weighted average number of common shares outstanding: Three months ended March 31, 2022 2021 Issued common shares at beginning of period 85,545,875 77,961,151 Effect of shares issued 480,798 8,333 Weighted average number of common shares outstanding – basic 86,026,673 77,969,484 Weighted average number of shares outstanding – diluted 86,026,673 77,969,484 There is no difference in diluted as compared to basic earnings per share as the impact would be antidilutive as a result of the net loss.

Operating lease and other commi

Operating lease and other commitments	3 Months Ended
	Mar. 31, 2022
Operating lease and other commitments	5. Operating lease and other commitments Effective for annual reporting periods beginning on or after January 1, 2019, IFRS 16 introduced a new approach to lessee accounting that requires a lessee to recognize assets and liabilities for the rights and obligations created by leases. IFRS 16 requires a lessee to recognize assets and liabilities for all leases with a term of more than 12 months. The IASB concluded that such an approach will result in a more faithful representation of a lessee’s assets and liabilities and, together with enhanced disclosures, greater transparency of a lessee’s financial leverage and capital employed. We adopted this standard on January 1, 2019, with an immaterial cumulative adjustment of $11,667 to accumulated deficit rather than retrospectively adjusting prior periods. We used an incremental borrowing rate as a discount rate for our operating leases. The discount rate ranges from 4.75% to 5.00% and the average remaining years for our lease are 1.46 years as of March 31, 2022. The following table provides the changes in the Corporation’s operating lease right-of-use assets for the three months ended March 31, 2022 and 2021 respectively: (amounts in dollars) Total Balances as of January 1, 2022 $ 383,969 Renewed office lease - Accumulated amortization (55,499 ) Balances as of March 31, 2022 $ 328,470 (amounts in dollars) Total Balances as of January 1, 2021 $ 422,297 Renewed office lease - Accumulated amortization (55,606 ) Balances as of March 31, 2021 $ 366,691 The following table provides the changes in the Corporation’s operating lease liability for the three months ended March 31, 2022 and 2021 respectively: (amounts in dollars) Total Balances as of January 1, 2022 $ 391,459 Renewed office lease - Repayments of lease liability (58,520 ) Other 5,962 Balances as of March 31, 2022 $ 338,901 Lease liability due within one year $ 231,231 Lease liability long term $ 107,670 (amounts in dollars) Total Balances as of January 1, 2021 $ 425,620 Renewed office lease - Repayments of lease liability (59,889 ) Other 5,279 Balances as of March 31, 2021 $ 371,010 Lease liability due within one year $ 168,197 Lease liability long term $ 202,813 The total future commitment payment amount for above lease is $350,760 comparing an outstanding lease liability of $338,901 as of March 31, 2022. The difference is due to interest expense. In addition to the lease commitment, the corporation has a future insurance premium payment and copier rent of $118,916 as of March 31,2022.

New Drug Application (NDA) Expe

New Drug Application (NDA) Expense	3 Months Ended
	Mar. 31, 2022
New Drug Application (NDA) Expense	6. New Drug Application (NDA) Expense In March,2022, the Company submitted it’s New Drug Application (NDA) to the FDA for Fexapotide Triflutate to seek marketing approval in the U.S. for Fexapotide Triflutate for the treatment of men with benign prostatic hyperplasia (BPH). The company paid a total of $3,117,218 for the application fee and recorded as R&D expense. Following the FDA guidance of industry user fee waivers, reductions and refund for drug products, the Company expects it will receive a full refund for the application fee.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transaction	7. Related Party Transactions: The transactions we have with related parties include compensation arrangements for current compensation, share based compensation , and compensation under options, and share purchase as investor. Executive officers and directors participate in the Corporation’s stock option plan. Certain Executive officers are covered under the Corporation’s health plan. Key management personnel compensation is comprised of: Three months ended March 31, 2022 2021 Salaries and bonus $ 300,000 $ 250,000 Short-term employee benefits 584 584 Stock-based compensation 62,267 229,188 $ 362,851 $ 479,772 Total honorariums to the independent directors of the Corporation for participating in Board and Committee meetings were nil for the period ended March 31, 2022 and 2021, respectively. Our Chief Financial Officer receives no salary compensation as an individual and receives no deferred or incentive compensation. We do make payments based on contract for services rendered to a corporation controlled by him. Amounts paid under this arrangement were $40,000 for the period ended March 31, 2022 and $120,000 for the period ended March 31, 2021, respectively. Our Corporate Legal Counsel receives no salary compensation as an individual and receives no deferred or incentive compensation. We do make payments based on contract for services rendered to a corporation controlled by him. Amounts paid under this arrangement were $97,500 for the period ended March 31, 2022 and $81,198 for the period ended March 31, 2021, respectively. One of directors, James G. Robinson, purchased 1,151,515 shares of common stock at a purchase price of $1.65 per share for a total value of 1.9M in the company’s financing in March,2022. Concurrently with the closing of the Offering, he received warrants to purchase up to an aggregate of 1,151,515 shares of common stock, at an initial exercise price equal to $2.00 per share and will expire on the five-year anniversary of the Effective Date. The 1.9M was recorded as share capital subscription receivable for the period ended March 31,2022.

Subsequent events

Subsequent events	3 Months Ended
	Mar. 31, 2022
Subsequent events	8. Subsequent events: The Corporation has evaluated subsequent events through May 13, 2022, the date the financial statements were authorized for issuance by the Audit Committee of the Board of Directors. The corporation has determined there are no subsequent events except the following. On April 29,2022, the Corporation received share capital subscription receivable of 1.9M from its director, James G. Robinson.

Basis of preparation (Policies)

Basis of preparation (Policies)	3 Months Ended
	Mar. 31, 2022
Statement of compliance	(a) Statement of compliance: The consolidated condensed unaudited interim consolidated financial statements of the Corporation have been prepared in accordance with International Financial Reporting Standards (“IFRS”) and its interpretations as issued by the International Accounting Standards Board (“IASB”) and in accordance with IAS 34, Interim Financial Reporting The consolidated condensed interim consolidated financial statements were authorized for issuance by the Board of Directors on May 13, 2022.
Basis of measurement	The condensed unaudited interim consolidated financial statements have been prepared on a going concern and on the historical cost basis. The functional currency of the Corporation is the US dollar.
Use of estimates and judgments	The preparation of the consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. Information about critical judgments in applying accounting policies and assumption and estimation uncertainties that have the most significant effect on the amounts recognized in the consolidated financial statements is noted below: Significant estimates include, but are not limited to, the estimation of useful lives of equipment for purposes of depreciation, useful life of lease for purpose of amortization and the valuation of common shares and stock option issued for services.

Share capital (Tables)

Share capital (Tables)	3 Months Ended
	Mar. 31, 2022
Summary of Stock option award	Options outstanding Weighted Weighted average average remaining exercise contractual Number Price life (in years) Outstanding, December 31, 2021 6,428,000 $ 1.81 3.86 Expired - - - Cancelled - - - Granted - - - Outstanding, March 31, 2022 6,428,000 $ 1.81 3.61 Options exercisable 6,361,333 $ 1.80 3.57
Summary of stock option-based compensation expense	Three months ended March 31, Employee expense 2022 2021 Stock and stock option compensation granted in 2015 62,267 229,188 2020 32,369 52,858 Total stock-based compensation expense recognized $ 94,636 $ 282,046 Three months ended March 31, 2022 2021 Stock-based compensation pertaining to general and administrative expenses $ 31,133 $ 114,594 Stock-based compensation pertaining to research and development expenses 63,503 167,452 Total $ 94,636 $ 282,046

Operating leases and other comm

Operating leases and other commitment (Tables)	3 Months Ended
	Mar. 31, 2022
Summary of Operating lease right-of-use assets	(amounts in dollars) Total Balances as of January 1, 2022 $ 383,969 Renewed office lease - Accumulated amortization (55,499 ) Balances as of March 31, 2022 $ 328,470 (amounts in dollars) Total Balances as of January 1, 2021 $ 422,297 Renewed office lease - Accumulated amortization (55,606 ) Balances as of March 31, 2021 $ 366,691
Summary of operating lease liability	(amounts in dollars) Total Balances as of January 1, 2022 $ 391,459 Renewed office lease - Repayments of lease liability (58,520 ) Other 5,962 Balances as of March 31, 2022 $ 338,901 Lease liability due within one year $ 231,231 Lease liability long term $ 107,670 (amounts in dollars) Total Balances as of January 1, 2021 $ 425,620 Renewed office lease - Repayments of lease liability (59,889 ) Other 5,279 Balances as of March 31, 2021 $ 371,010 Lease liability due within one year $ 168,197 Lease liability long term $ 202,813

Earning Per Share (Tables)

Earning Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share	Three months ended March 31, 2022 2021 Issued common shares at beginning of period 85,545,875 77,961,151 Effect of shares issued 480,798 8,333 Weighted average number of common shares outstanding – basic 86,026,673 77,969,484 Weighted average number of shares outstanding – diluted 86,026,673 77,969,484

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2022
Related Party	Three months ended March 31, 2022 2021 Salaries and bonus $ 300,000 $ 250,000 Short-term employee benefits 584 584 Stock-based compensation 62,267 229,188 $ 362,851 $ 479,772

Share capital (Details)

Share capital (Details) - Equity Option [Member]	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Statement [Line Items]
Number of outstanding balance, Beginning | shares	6,428,000
Cancelled | shares	0
Number of outstanding balance, Ending | shares	6,428,000
Options exercisable | shares	6,361,333
Weighted average exercise price, Beginning	$ 1.81
Weighted average exercise price, Expired	0
Weighted average exercise price, Cancelled	0
Weighted average exercise price, Granted	0
Weighted average exercise price, Ending	1.81
Weighted average exercise price, Options exercisable	$ 1.80
Weighted average remaining contractual life (in years), Beginning	3 years 10 months 9 days
Weighted average remaining contractual life (in years), Granted	0 years
Weighted average remaining contractual life (in years), Ending	3 years 7 months 9 days
Weighted average remaining contractual life options exercisable (in years)	3 years 6 months 25 days

Share capital (Details 1)

Share capital (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Shares based compensation recognized expense	$ 94,636	$ 282,046
2015 [Member]
Statement [Line Items]
Shares based compensation recognized expense	62,267	229,188
2020 [Member]
Statement [Line Items]
Shares based compensation recognized expense	$ 32,369	$ 52,858

Share capital (Details 2)

Share capital (Details 2) - Equity Option [Member] - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Stock-based compensation pertaining to general and administrative expenses	$ 31,133	$ 114,594
Stock-based compensation pertaining to research and development expenses	63,503	167,452
Total	$ 94,636	$ 282,046

Share capital (Details Narrativ

Share capital (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2019	Jun. 30, 2021
Private Placements [Member]
Statement [Line Items]
Warrants issued	3,878,789	2,500,000	2,018,348
Warrant value		$ 200,000	$ 330,277
Exercise price or warrants	$ 2	$ 8	$ 2.50
Common stock shares issued	193,939
Common stock exercise price	$ 2.06
Warrants of additional paid in capital	$ 1,877,608
Stock Option [Member]
Statement [Line Items]
Options available for granting	8,572,000
Shares issuable upon exercise of warrants, maximum	15,000,000
Percentage of issued and outstanding shares issuable maximum to one individual	15.00%

Earnings per share (Details)

Earnings per share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Issued common shares at beginning of period	85,545,875	77,961,151
Effect of shares issued	480,798	8,333
Weighted average number of common shares outstanding - basic	86,026,673	77,969,484
Weighted average number of shares outstanding - diluted	86,026,673	77,969,484

Operating leases and other co_2

Operating leases and other commitment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Begininng balance	$ 383,969	$ 422,297
Renewed office lease	0	0
Accumulated amortization	(55,499)	(55,606)
Ending balance	$ 328,470	$ 366,691

Operating leases and other co_3

Operating leases and other commitment (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Beginning balance	$ 391,459	$ 425,620
Renewed office lease	0	0
Repayments of lease liability	(58,520)	(59,889)
Other	5,962	5,279
Ending balance	338,901	371,010
Lease liability due within one year	231,231	168,197
Lease liability long term	$ 107,670	$ 202,813

Operating leases and other co_4

Operating leases and other commitment (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Statement [Line Items]
Operating lease liability	$ 338,901	$ 391,459	$ 371,010	$ 425,620
Future payment amount and copier rent	118,916
Future payment amount	350,760
January 1, 2019 [Member]
Statement [Line Items]
Immaterial cumulative adjustment	$ 11,667
Description average remaining life and discount rate	The discount rate ranges from 4.75% to 5.00% and the average remaining years for our lease are 1.46 years as of March 31, 2022

New Drug Application (Details N

New Drug Application (Details Narrative)	3 Months Ended
	Mar. 31, 2022USD ($)
R&D expense	$ 3,117,218

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Stock-based compensation		$ 282,000
Director [Member]
Statement [Line Items]
Salaries	$ 300,000	250,000
Short-term employee benefits	584	584
Stock-based compensation	62,267	229,188
Total	$ 362,851	$ 479,772

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Statement [Line Items]
Share capital subscription receivable	$ (2,489,000)		$ (589,000)
Corporate Legal Counsel [Member]
Statement [Line Items]
Amounts paid contract for services	40,000	$ 120,000
Chief Financial Officers [Member]
Statement [Line Items]
Amounts paid contract for services	97,500	$ 81,198
James G. Robinson [Member]
Statement [Line Items]
Share capital subscription receivable	$ 1,900,000
Purchase price	$ 1.65
Total value	1,900,000
Warrants purchase	1,151,515
Purchase shares of common stock	1,151,515
Exercise price	$ 2

Subsequent events (Details Narr

Subsequent events (Details Narrative) - USD ($) $ in Thousands	Apr. 29, 2022	Mar. 31, 2022	Dec. 31, 2021
Statement [Line Items]
Share capital subscription receivable		$ (2,489)	$ (589)
Subsequent Events
Statement [Line Items]
Share capital subscription receivable	$ 1,900